Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

Launched by M.D. ANDERSON CANCER CENTER · Apr 24, 2017

Keywords

ClinConnect Summary

This clinical trial is exploring how well a medication called tranexamic acid can help reduce blood loss in patients who have pelvic tumors and are scheduled for a specific type of surgery called hemipelvectomy. This surgery involves removing part of the pelvis and may lead to significant bleeding, so the goal is to see if tranexamic acid can help stabilize blood clots and prevent excessive bleeding during and after the operation.

Both children and adults with a pelvic tumor who are having this surgery at the University of Texas MD Anderson Cancer Center may be eligible to participate. It's important to note that some patients, like those with certain health conditions or who are pregnant or breastfeeding, may not qualify. Participants will receive the medication during their surgery, and the research team will monitor how well it works in reducing blood loss. This trial is currently recruiting, so if you or someone you know is interested, it’s a good idea to talk to a doctor for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Both pediatric and adult patients can be eligible to participate
• • Cognitively impaired and non-English speakers can be eligible to participate.
• • Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
• Exclusion Criteria:
• • Patient with a history of genetic prothrombotic state
• • Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
• • Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction
• • Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment
• • Patients will not be eligible if they have a history of color vision defects
• • Patients will not be eligible if they have a history of retinal vein or artery occlusion
• • Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
• • Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
• • Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73m2)
• • Patients will not be eligible if they present or have a history of seizure disorder